Iovance Biotherapeutics Inc (NASDAQ: IOVA) on Friday, plunged -6.13% from the previous trading day, before settling in for the closing price of $2.61. Within the past 52 weeks, IOVA’s price has moved between $1.64 and $7.03.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 4.17%. The company achieved an average annual earnings per share of 15.81%. With a float of $338.65 million, this company’s outstanding shares have now reached $385.46 million.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Iovance Biotherapeutics Inc is 14.69%, while institutional ownership is 47.05%. The most recent insider transaction that took place on Jun 05 ’25, was worth 55,200. In this transaction Chief Commercial Officer of this company bought 30,000 shares at a rate of $1.84, taking the stock ownership to the 30,000 shares. Before that another transaction happened on May 23 ’25, when Company’s Chief Regulatory Officer bought 5,600 for $1.74, making the entire transaction worth $9,743. This insider now owns 206,852 shares in total.
Iovance Biotherapeutics Inc (IOVA) Earnings and Forecasts
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.26 earnings per share (EPS) for the period topping the consensus outlook (set at -0.27) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 45.62% during the next five years compared to 4.17% growth over the previous five years of trading.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) Trading Performance Indicators
Iovance Biotherapeutics Inc (IOVA) is currently performing well based on its current performance indicators. A quick ratio of 3.00 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.59 in one year’s time.
